content material coming from — ca.movies.yahoo.com
GlobeNewswire
Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX
CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (the “Firm”) (Nasdaq: VYNT), is a brand new power in drug discovery targeted on integrating human-powered scientific and technology-based programs to de-risk and speed up the invention and growth of therapeutics for biopharma companions in addition to for the proprietary pipeline of the Firm. At this time, Vyant Bio introduced that an investor webcast can be hosted on Tuesday, April 6, 2021. Jay Roberts, Chief Government Officer of Vyant Bio, will focus on company, scientific, and operational updates in relation to the Firm’s current merger between the predecessor, Most cancers Genetics, Inc., and StemoniX, Inc. Mr. Roberts can be joined on the decision by Vyant Bio’s Chief Innovation Officer, Ping Yeh, and Chief Monetary Officer, Andy LaFrence. Please additionally go to the Traders’ part of the Vyant Bio site for particulars on take part. Occasion: Investor Webcast – Announcement of Vyant BioDate: Tuesday, April 6, 2021Time: 4:30pm ETWebcast: https://edge.media-server.com/mmc/p/sxogu3xt Dial In: (844) 954-2324 Convention ID: 9757240 A stay and archived webcast of the convention name can even be obtainable contained in the Traders part of the Vyant Bio company web site at www.vyantbio.com. ABOUT VYANT BIO, INC. Vyant Bio, Inc. (“Vyant Bio” or “Firm”) operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Firm is executing on the mixing of those two main companies to combine human-powered scientific and technology-based programs and experience with years of preclinical expertise to de-risk and speed up discovery and growth of preclinical and scientific pipelines for biopharma companions in addition to for the proprietary pipeline of the Firm. StemoniX is empowering the invention of recent medicines by means of the convergence of novel human biology and software program applied sciences. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and growth. Predictive, correct, and constant, these human fashions allow scientists to shortly and economically conduct analysis with improved outcomes in a simplified workflow. By way of collaborations with drug discovery organizations, StemoniX exams compounds in-house, creates new cell-based illness fashions, and operationalizes customized human iPSC-derived illness fashions at massive scale for high-throughput screening. With modern iPSC applied sciences and information science, StemoniX helps world establishments convey essentially the most promising medicines to sufferers. vivoPharm affords proprietary preclinical take a look at programs supporting scientific diagnostic choices at early levels valued by the pharmaceutical trade, biotechnology corporations, and tutorial analysis facilities. vivoPharm is targeted on precision and translational drugs to drive drug discovery and novel therapies. vivoPharm focuses on conducting research tailor-made to information drug growth, ranging from compound libraries and ending with a complete set of in vitro and in vivo information and stories, as wanted for Investigational New Drug filings. vivoPharm operates in The Affiliation for Evaluation and Accreditation of Laboratory Animal Care Worldwide (AAALAC) accredited and GLP compliant audited services. For extra data, please go to or observe Vyant Bio at: Web: www.vyantbio.com LinkedIn: https://www.linkedin.com/firm/vyant-bio Twitter: @VyantBio Ahead Trying Statements: This press launch incorporates forward-looking statements throughout the that means of the Personal Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s (previously Most cancers Genetics, Inc.) expectations concerning future monetary and/or working outcomes, and potential for our companies, future revenues or development, or the potential for future strategic transactions on this press launch represent forward-looking statements. Any statements that aren’t historic reality (together with, however not restricted to, statements that comprise phrases resembling “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) also needs to be thought of to be forward-looking statements. Ahead-looking statements contain dangers and uncertainties, together with, with out limitation, dangers inherent in our makes an attempt to adapt to the worldwide coronavirus pandemic, obtain profitability and improve gross sales of our pre-clinical companies, preserve our current buyer base and keep away from cancelation of buyer contracts or discontinuance of trials, increase capital to fulfill our liquidity wants, notice the anticipated advantages of the merger with StemoniX, Inc., and different dangers mentioned within the Vyant Bio, Inc. Type 10-Okay for the 12 months ended December 31, 2020, together with different filings with the Securities and Trade Fee. These forward-looking statements converse solely as of the date hereof. Most cancers Genetics, Inc. disclaims any obligation to replace these forward-looking statements. Investor Contacts: Jennifer Okay. Zimmons. Ph.D. Investor Relations Zimmons Worldwide Communications, Inc. E-mail: jzimmons@zimmonsic.com Telephone: +1.917.214.3514 Supply: Vyant Bio, Inc. ###
— to ca.movies.yahoo.com
